1333382-30-1
1333382-30-1
Chemical Structure
CX-5011
- CAS No.: 1333382-30-1
- Formula:C20H11N4NaO2
- Molecular Weight:362.32
IUPAC Name: sodium 5-((3-ethynylphenyl)amino)pyrimido[4,5-c]quinoline-8-carboxylate
InChIKey: FSIFELDKZUCPMJ-UHFFFAOYSA-M
SMILES: O=C(C1=CC=C2C3=CN=CN=C3C(NC4=CC=CC(C#C)=C4)=NC2=C1)O[Na]
Biological Activity: CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CX-5011 | 99.48% | CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. D'Amore C, et al. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms. Biochim Biophys Acta Mol Cell Res. 2020 Nov;1867(11):118807. [Content Brief]
- [2]. Salizzato V, et al. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Oncotarget. 2016 Apr 5;7(14):18204-18. [Content Brief]
